30.06.2013 Views

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

pharmaceutical needs <strong>of</strong> people whose circumstances are considered<br />

‘exceptional’ and whose needs are not able to be met by <strong>the</strong> first purpose.<br />

Theme 1, ‘PHARMAC <strong>the</strong> Success Story’ demonstrated <strong>the</strong> efficiency <strong>of</strong><br />

PHARMAC’s procurement policies. These were described as highly effective<br />

aggressive monopsonistic purchasing practices that have attracted both positive<br />

and negative international attention.<br />

Cumming et al. (2010) commented positively on New Zealand Treasury’s reports<br />

on PHARMAC. These reports showed that PHARMAC had limited <strong>the</strong> cost <strong>of</strong><br />

medicines in New Zealand to an average annual rate <strong>of</strong> increase <strong>of</strong> 2% between<br />

1994 and 2008. This compared with an annual rate <strong>of</strong> increase in <strong>the</strong> cost <strong>of</strong><br />

medicines <strong>of</strong> 15% in <strong>the</strong> 1980s (Cumming, et al., 2010). Cumming et al noted<br />

that between 1994 and 2008 <strong>the</strong>re was an overall annual rise in public health<br />

spending <strong>of</strong> 7.2%. Finally, <strong>the</strong>ir research has shown that as a result <strong>of</strong><br />

PHARMAC’s procurement policies, subsidy management and cost containment<br />

activities between 1993 and 2007, <strong>the</strong> New Zealand tax payer has been saved<br />

$1.17 billion.<br />

The OECD Report on Health Spending in 2010 described New Zealand as a<br />

country with <strong>the</strong> lowest cost per drug category in <strong>the</strong> OECD range <strong>of</strong> countries<br />

(OECD, 2010). PHARMAC has made a strong contribution to <strong>the</strong> New Zealand<br />

economy, and more particularly to health services, by providing access to<br />

medicines through subsidies at internationally lowest prices.<br />

This success has been achieved largely by PHARMAC’s use <strong>of</strong> <strong>the</strong> exemption<br />

from Part II <strong>of</strong> <strong>the</strong> Commerce Act (1986), which provides PHARMAC with <strong>the</strong><br />

freedom to act in this manner. PHARMAC’s procurement practices required<br />

sellers to group <strong>the</strong>ir patented drugs with generic drugs when negotiating<br />

purchasing contracts with PHARMAC. Sellers were also required to reference <strong>the</strong><br />

price <strong>of</strong> all <strong>the</strong> drugs in each drug category to <strong>the</strong> cheapest priced drug. In<br />

addition, PHARMAC has extensively purchased generic medicines in favour <strong>of</strong><br />

patented medicines. These practices have reduced <strong>the</strong> ability <strong>of</strong> <strong>the</strong> holder <strong>of</strong><br />

218

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!